绝经期妇女乳腺癌的不同药物治疗及预后影响因素分析

摘要

目的 分析替吉奥对照卡培他滨治疗绝经期妇女晚期乳腺癌的效果、安全性并探讨患者预后的影响因素.方法 以2013年1月～2015年6月南充市中心医院肿瘤内科收治的绝经期妇女晚期乳腺癌患者61例为研究对象,采用随机数字表法将患者分为替吉奥组(31例)和卡培他滨组(30例).对比分析两组的临床疗效和预后的影响因素.结果 替吉奥组及卡培他滨组的总有效率(32.26％ vs.30.00％,x2=0.036,P=0.849)、疾病控制率(67.74％ vs.63.33％,x2=0.131,P=0.717),差异均无统计学意义;两组中位术后无复发生存时间差异无统计学意义(5.7个月vs.5.1个月,x2=0.107,P=0.744);替吉奥组高胆红素血症发生率高于卡培他滨组(x2=10.227,P=0.001),而卡培他滨组手足综合症发生率高于替吉奥组高胆(x2=10.377,P=0.001);无复发生存时间、转移灶数目为患者PFS的独立影响因素.结论 替吉奥与卡培他滨治疗绝经期妇女晚期乳腺癌的临床疗效相当,均能取得较好的疗效,不良反应略有差异,但均可耐受.%Objective To analyze the efficacy,safety and the related factors of S-1 and Capecitabine in treatment of advanced breast cancer in postmenopausal women's.Methods From January 2013 to June 2015,61 cases of menopausal women with advanced breast cancer admitted to Department of Oncology in Nanchong Central Hospital were selected as subjects,and all subjects were randomly divided into S-1 treatment group (31 cases) and Capecitabine treatment group (30 cases) by random number table.The clinical efficacy and prognosis of the two groups were compared and prognostic factors of all patients were analyzed.Results There was no significant difference in rate of ORR (32.26％ vs.30％,x2=0.036,P=0.849),DCR (67.74％ vs.63.33％,x2=0.131,P=0.717) in S-1 group and Capecitabine group,and there was no significant difference in median PFS time between the two groups (5.7 months vs.5.1 months,x2=0.107,P=0.744).The incidence of hyperbilirubinemia of the S-1 group was higher than that of the Capecitabine group (x2=10.227,P=0.001),and the incidence of hand foot syndrome of the Capecitabine group was higher than that of the S-1 group (x2=10.377,P=0.001).Disease free survival and the number of metastases was independent factors of PFS.Conclusion The clinical efficacy of S-1 and Capecitabine in treatment of advanced breast cancer in postmenopausal women is equivalent,and all can obtain good curative effect,the adverse reaction is slightly different,but all can be tolerated.